Integra LifeSciences Holdings NasdaqGS:IART Stock Report

Independent Director recently sold US$446k worth of stock

On the 5th of August, Raymond Murphy sold around 8k shares on-market at roughly US$55.78 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$917k more than they bought in the last 12 months.

An unknown buyer entered into a definitive agreement to acquire Non-core Traditional Wound Care Business of Integra LifeSciences Holdings Corporation (NasdaqGS:IART) for $28.8 million.

An unknown buyer entered into a definitive agreement to acquire Non-core Traditional Wound Care Business of Integra LifeSciences Holdings Corporation (NasdaqGS:IART) for $28.8 million on May 20, 2022. The consideration for $28.8 million, consisting of $27.8 million in cash plus $1 million in milestone payments which may be received upon achieving certain revenue-based performance milestones. Revenues for the TWC business were approximately $27 million in 2021. The transaction is subject to the satisfaction of customary closing conditions and is expected to close at or around the end of August 2022.

Second quarter 2022 earnings: EPS exceeds analyst expectations

Second quarter 2022 results: EPS: US$0.54 (up from US$0.41 in 2Q 2021). Revenue: US$397.8m (up 2.0% from 2Q 2021). Net income: US$44.8m (up 28% from 2Q 2021). Profit margin: 11% (up from 9.0% in 2Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 21%. Over the next year, revenue is forecast to grow 2.9%, compared to a 6.7% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.

Integra LifeSciences Holdings Corporation Revises Financial Guidance for the Third Quarter and Full Year 2022